243 related articles for article (PubMed ID: 33517888)
21. The effect of pregnancy on renal angiomyolipoma; a world of knowledge to gain, specifically in women with TSC.
Kluiving MW; Peeters EFHI; Lely TA; van Oorschot N; de Ranitz-Greven WL
BMC Nephrol; 2024 Mar; 25(1):113. PubMed ID: 38519911
[TBL] [Abstract][Full Text] [Related]
22. Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.
Brakemeier S; Bachmann F; Budde K
Pediatr Nephrol; 2017 Jul; 32(7):1137-1144. PubMed ID: 27585680
[TBL] [Abstract][Full Text] [Related]
23. Management of renal angiomyolipoma in patients with tuberous sclerosis complex.
Simmons JL; Hussain SA; Riley P; Wallace DM
Oncol Rep; 2003; 10(1):237-41. PubMed ID: 12469175
[TBL] [Abstract][Full Text] [Related]
24. Tuberous sclerosis complex and renal angiomyolipoma: case report and review of the literature.
Winterkorn EB; Daouk GH; Anupindi S; Thiele EA
Pediatr Nephrol; 2006 Aug; 21(8):1189-93. PubMed ID: 16791610
[TBL] [Abstract][Full Text] [Related]
25. Renal tumors in tuberous sclerosis complex.
Trnka P; Kennedy SE
Pediatr Nephrol; 2021 Jun; 36(6):1427-1438. PubMed ID: 33006051
[TBL] [Abstract][Full Text] [Related]
26. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex.
Wang W; Guo H; Shi B; Sun H; Li H; Zhang Y; Cai Y
Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282
[TBL] [Abstract][Full Text] [Related]
27. Renal angiomyolipoma-patient characteristics and treatment with focus on active surveillance.
Swärd J; Henrikson O; Lyrdal D; Peeker R; Lundstam S
Scand J Urol; 2020 Apr; 54(2):141-146. PubMed ID: 31971051
[No Abstract] [Full Text] [Related]
28. Renal manifestations of tuberous sclerosis complex.
Fatihi el M; Khanfri N; Niang A; Ghafel C; Hachim K; Zahiri K; Benghanem MG; Ramdani B; Zaid D
Ann Med Interne (Paris); 2003 Sep; 154(4):255-8. PubMed ID: 14593316
[TBL] [Abstract][Full Text] [Related]
29. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial.
Cai Y; Guo H; Wang W; Li H; Sun H; Shi B; Zhang Y
Orphanet J Rare Dis; 2018 Mar; 13(1):43. PubMed ID: 29587809
[TBL] [Abstract][Full Text] [Related]
30. Mutational analysis of renal angiomyolipoma associated with tuberous sclerosis complex and the outcome of short-term everolimus therapy.
Ni J; Yan F; Qin W; Yu L; Zhang G; Liu F; Yang X; Yang B; Hao C; Wang T; Liu P; Yuan J; Wu G
Sci Rep; 2019 Oct; 9(1):14337. PubMed ID: 31586081
[TBL] [Abstract][Full Text] [Related]
31. Renal angiomyolipoma with tuberous sclerosis complex: How it differs from sporadic angiomyolipoma in both management and care.
Hatano T; Egawa S
Asian J Surg; 2020 Oct; 43(10):967-972. PubMed ID: 31959574
[TBL] [Abstract][Full Text] [Related]
32. Differentiation of Sporadic Versus Tuberous Sclerosis Complex-Associated Angiomyolipoma.
Rabenou RA; Charles HW
AJR Am J Roentgenol; 2015 Aug; 205(2):292-301. PubMed ID: 26204278
[TBL] [Abstract][Full Text] [Related]
33. Effect of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: an evaluation based on tumor density.
Hatano T; Atsuta M; Inaba H; Endo K; Egawa S
Int J Clin Oncol; 2018 Jun; 23(3):547-552. PubMed ID: 29256023
[TBL] [Abstract][Full Text] [Related]
34. Changing trends in presentation, diagnosis and management of renal angiomyolipoma: comparison of sporadic and tuberous sclerosis complex-associated forms.
Seyam RM; Bissada NK; Kattan SA; Mokhtar AA; Aslam M; Fahmy WE; Mourad WA; Binmahfouz AA; Alzahrani HM; Hanash KA
Urology; 2008 Nov; 72(5):1077-82. PubMed ID: 18805573
[TBL] [Abstract][Full Text] [Related]
35. Concurrent Eosinophilic Solid and Cystic Renal Cell Carcinoma and Angiomyolipoma With Epithelial Cysts in the Setting of Tuberous Sclerosis Complex: A Rare Synchronous Occurrence of 2 Distinct Entities.
Cho WC; Collins K; Mnayer L; Cartun RW; Earle JS
Int J Surg Pathol; 2019 Oct; 27(7):804-811. PubMed ID: 31142207
[TBL] [Abstract][Full Text] [Related]
36. Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC).
Brakemeier S; Vogt L; Adams L; Zukunft B; Diederichs G; Hamm B; Budde K; Makowski MR
PLoS One; 2017; 12(12):e0189132. PubMed ID: 29232371
[TBL] [Abstract][Full Text] [Related]
37. Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors.
Rakowski SK; Winterkorn EB; Paul E; Steele DJ; Halpern EF; Thiele EA
Kidney Int; 2006 Nov; 70(10):1777-82. PubMed ID: 17003820
[TBL] [Abstract][Full Text] [Related]
38. Continuous low-dose everolimus shrinkage tuberous sclerosis complex-associated renal angiomyolipoma: a 48-month follow-up study.
Wei CC; Tsai JD; Sheu JN; Chen SL; Tsao TF; Yang SH; Tsai JD
J Investig Med; 2019 Mar; 67(3):686-690. PubMed ID: 30455224
[TBL] [Abstract][Full Text] [Related]
39. The association between computed tomography attenuation value of renal angiomyolipoma associated with tuberous sclerosis complex and response to everolimus.
Liao Z; Li J; Zhao Y; Wang Z; Wang X; Qiu D; Zhang Y
World J Urol; 2024 Jan; 42(1):10. PubMed ID: 38183428
[TBL] [Abstract][Full Text] [Related]
40. Concurrent angiomyolipomas and renal cell neoplasms in patients without tuberous sclerosis: a retrospective study.
Mei M; Rosen LE; Reddy V; Cimbaluk DJ; Gattuso P
Int J Surg Pathol; 2015 Jun; 23(4):265-70. PubMed ID: 25757955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
